Connecting Life Science with Market Strategy

Helping investment funds to make confident biotech decisions and life science startups to secure the capital they need to grow. Expert due diligence, scientific assessment, and fundraising advisory.

Why Work With Me

Leveraging a decade of cross-functional experience across biotech R&D and venture investment to deliver clarity and confidence in every engagement.

10+ Years Experience

Deep expertise spanning biotech R&D, venture capital advisory, and investment due diligence across the full funding lifecycle.

Due Diligence Expertise

Rigorous scientific and commercial assessment of biotech assets, de-risking investment decisions with data-driven analysis.

Dual Perspective

Uniquely positioned to understand both investor requirements and startup challenges, ensuring every deal is evaluated from all angles.

Proven Track Record

Instrumental in supporting over $500M in biotech funding rounds and providing due diligence for leading life science investment funds.

Featured Services

Advisory services for investment funds evaluating biotech opportunities and for startups preparing to raise their next round.

Investment Due Diligence

Comprehensive scientific and commercial assessments for funds evaluating biotech investments, minimising risk and maximising conviction.

Fundraising Strategy

End-to-end support for biotech startups preparing for Series A, B, or C rounds — from investor targeting to pitch refinement.

Scientific Assessment

Independent evaluation of technology platforms, clinical pipelines, and IP landscapes to inform sound investment decisions.

Client Perspectives

"AK Consulting's due diligence report gave our investment committee the scientific clarity we needed. Their ability to translate complex pipeline data into clear risk-reward assessments was invaluable to our decision process."

MS

Dr. Marcus Sterling

Managing Partner, BioVenture Capital

"AK Consulting transformed how we approached our Series B raise. They identified the right investors, sharpened our scientific narrative, and prepared us thoroughly — we closed the round in record time."

JC

Julia Chen

CEO, NexaCell Therapeutics